NFlection
is a Pennsylvania-based biopharmaceutical company that develops and commercializes novel therapies for treating patients with neurofibromatosis... Read moreNFlection
is a Pennsylvania-based biopharmaceutical company that develops and commercializes novel therapies for treating patients with neurofibromatosis... Read more
News
Oct 22, 2021
The Business Journals
NFlection: Lab Notes: NFlection names new CEO; Immunocore enters into cancer drug partnership
Aug 17, 2021
MarketScreener
NFlection: NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1
May 26, 2021
PR Newswire
Press Release: NFlection : NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial
Jul 09, 2020
Xconomy
NFlection: NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep
Jun 10, 2020
The Business Journals: Philadelphia
NFlection: Wayne biopharm firm raises $20M to advance lead drug candidate
Jun 09, 2020
FIRSTWORD PHARMA
NFlection: NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis
May 01, 2020
The Business Journals: Philadelphia
NFlection Therapeutics, Inc: Wayne biopharma firm targeting rare genetic disorders raises $6M
NFlection Competitors
1
2
3
4
5
6